ZA201504521B - Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same - Google Patents
Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the sameInfo
- Publication number
- ZA201504521B ZA201504521B ZA2015/04521A ZA201504521A ZA201504521B ZA 201504521 B ZA201504521 B ZA 201504521B ZA 2015/04521 A ZA2015/04521 A ZA 2015/04521A ZA 201504521 A ZA201504521 A ZA 201504521A ZA 201504521 B ZA201504521 B ZA 201504521B
- Authority
- ZA
- South Africa
- Prior art keywords
- propyl
- diisobutylamino
- piperazin
- imidazol
- benzo
- Prior art date
Links
- KLKKWCPJBTXWOV-UHFFFAOYSA-N n-[3-[4-[3-[bis(2-methylpropyl)amino]propyl]piperazin-1-yl]propyl]-1h-benzimidazol-2-amine Chemical class C1CN(CCCN(CC(C)C)CC(C)C)CCN1CCCNC1=NC2=CC=CC=C2N1 KLKKWCPJBTXWOV-UHFFFAOYSA-N 0.000 title 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12306690 | 2012-12-27 | ||
| PCT/EP2013/078068 WO2014102339A1 (en) | 2012-12-27 | 2013-12-27 | Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201504521B true ZA201504521B (en) | 2016-11-30 |
Family
ID=47501005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2015/04521A ZA201504521B (en) | 2012-12-27 | 2015-06-23 | Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US9562018B2 (enExample) |
| EP (1) | EP2938597B1 (enExample) |
| JP (1) | JP6384923B2 (enExample) |
| KR (1) | KR102115060B1 (enExample) |
| CN (1) | CN105008333B (enExample) |
| AU (2) | AU2013369288B2 (enExample) |
| BR (1) | BR112015015474B1 (enExample) |
| CA (1) | CA2895285C (enExample) |
| DK (1) | DK2938597T3 (enExample) |
| ES (1) | ES2605494T3 (enExample) |
| HR (1) | HRP20161612T2 (enExample) |
| HU (1) | HUE030930T2 (enExample) |
| IL (1) | IL239450B (enExample) |
| LT (1) | LT2938597T (enExample) |
| MX (1) | MX363367B (enExample) |
| NZ (1) | NZ708959A (enExample) |
| PL (1) | PL2938597T3 (enExample) |
| PT (1) | PT2938597T (enExample) |
| RS (1) | RS55511B1 (enExample) |
| RU (1) | RU2655454C2 (enExample) |
| SI (1) | SI2938597T1 (enExample) |
| WO (1) | WO2014102339A1 (enExample) |
| ZA (1) | ZA201504521B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105008333B (zh) | 2012-12-27 | 2018-02-09 | 雅尔兹普罗泰特公司 | N‑(3‑(4‑(3‑(二异丁基氨基)丙基)哌嗪‑1‑基)丙基)‑1H‑苯并[d]咪唑‑2‑胺的硫酸盐、其制备及其用途 |
| HK1245272B (en) | 2015-03-16 | 2019-09-27 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Novel 1,4-bis(3-aminopropyl)piperazine derivative and its use |
| TWI744300B (zh) * | 2016-03-23 | 2021-11-01 | 里爾中央醫學中心 | 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途 |
| CN116249693A (zh) * | 2020-10-01 | 2023-06-09 | 雅尔兹普罗泰特公司 | N-(3-(4-(3-(二异丁基氨基)丙基)哌嗪-1-基)丙基)-1H-苯并[d]咪唑-2-胺的琥珀酸盐，其制备及其用途 |
| JP7500875B2 (ja) * | 2020-10-07 | 2024-06-17 | アルツプロテクト | 運動ニューロン疾患及び神経筋接合部障害の処置のためのｎ－（３－（４－（３－（ジイソブチルアミノ）プロピル）ピペラジン－１－イル）プロピル）－１ｈ－ベンゾ［ｄ］イミダゾール－２－アミン硫酸塩及びそれらの溶媒和物の使用 |
| IL313403A (en) * | 2021-12-20 | 2024-08-01 | Alzprotect | USE OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[d]IMIDAZOL-2-AMINE SUCCINATE SALTS AND SOLVATES THEREOF FOR THE TREATMENT OF MOTOR NEURON DISEASES AND NEUROMUSCULAR JUNCTION DISORDERS |
| ES3075524T3 (en) | 2022-03-25 | 2026-08-05 | Alzprotect | Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine salts and solvates thereof for the treatment of sensory neuron diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2674856B1 (fr) * | 1991-04-05 | 1993-07-30 | Esteve Labor Dr | Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments. |
| JP2001500162A (ja) * | 1997-06-12 | 2001-01-09 | トランジェーヌ、ソシエテ、アノニム | 少なくとも１種の治療上有効な物質、特にポリヌクレオチド、を標的細胞に導入するための新規脂質複合体および遺伝子治療における使用 |
| CN1325397A (zh) * | 1998-09-30 | 2001-12-05 | 纽罗根公司 | 2－哌嗪烷基氨基苯并吡咯衍生物∶多巴胺受体亚型特异配体 |
| WO2002096431A1 (en) * | 2001-05-25 | 2002-12-05 | The Regents Of The University Of California | Optically active compounds clearing malformed proteins |
| US20040116441A1 (en) * | 2002-10-30 | 2004-06-17 | Pfizer Inc | Methods of using sulfonic acid derivatives |
| CA2509406C (en) * | 2002-12-23 | 2012-07-03 | Janssen Pharmaceutica N.V. | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| EP1809288B1 (en) * | 2004-11-10 | 2011-09-14 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases |
| CN105008333B (zh) * | 2012-12-27 | 2018-02-09 | 雅尔兹普罗泰特公司 | N‑(3‑(4‑(3‑(二异丁基氨基)丙基)哌嗪‑1‑基)丙基)‑1H‑苯并[d]咪唑‑2‑胺的硫酸盐、其制备及其用途 |
-
2013
- 2013-12-27 CN CN201380068524.8A patent/CN105008333B/zh active Active
- 2013-12-27 KR KR1020157017192A patent/KR102115060B1/ko active Active
- 2013-12-27 EP EP13815780.5A patent/EP2938597B1/en active Active
- 2013-12-27 SI SI201330408A patent/SI2938597T1/sl unknown
- 2013-12-27 RS RS20161055A patent/RS55511B1/sr unknown
- 2013-12-27 PL PL13815780T patent/PL2938597T3/pl unknown
- 2013-12-27 CA CA2895285A patent/CA2895285C/en active Active
- 2013-12-27 PT PT138157805T patent/PT2938597T/pt unknown
- 2013-12-27 LT LTEP13815780.5T patent/LT2938597T/lt unknown
- 2013-12-27 NZ NZ70895913A patent/NZ708959A/en unknown
- 2013-12-27 RU RU2015130671A patent/RU2655454C2/ru active
- 2013-12-27 AU AU2013369288A patent/AU2013369288B2/en active Active
- 2013-12-27 HR HRP20161612TT patent/HRP20161612T2/hr unknown
- 2013-12-27 WO PCT/EP2013/078068 patent/WO2014102339A1/en not_active Ceased
- 2013-12-27 DK DK13815780.5T patent/DK2938597T3/en active
- 2013-12-27 MX MX2015008502A patent/MX363367B/es unknown
- 2013-12-27 ES ES13815780.5T patent/ES2605494T3/es active Active
- 2013-12-27 US US14/655,642 patent/US9562018B2/en active Active
- 2013-12-27 HU HUE13815780A patent/HUE030930T2/hu unknown
- 2013-12-27 BR BR112015015474-3A patent/BR112015015474B1/pt active IP Right Grant
- 2013-12-27 JP JP2015550088A patent/JP6384923B2/ja active Active
-
2015
- 2015-06-16 IL IL239450A patent/IL239450B/en active IP Right Grant
- 2015-06-23 ZA ZA2015/04521A patent/ZA201504521B/en unknown
-
2016
- 2016-12-22 US US15/388,349 patent/US10537569B2/en active Active
-
2018
- 2018-03-28 AU AU2018202218A patent/AU2018202218B2/en active Active
-
2019
- 2019-08-27 US US16/552,436 patent/US10772884B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2022033I1 (el) | Παραγωγα βενζαμιδιου για την αναστολη της δραστικοτητας των abl1, abl2 και bcr-abl1 | |
| IL239450B (en) | Sulfate salts of n-(3-(4-(3-diisobutylamino)propyl)piperazine-1-yl)propyl)-h1-benzo[d]imidazol-2-amine, their preparation and use | |
| HUS2100032I1 (hu) | Helyettesített 5-fluor-1H-pirazolopiridin-származékok és alkalmazásuk | |
| ZA201404189B (en) | 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists | |
| ZA201304009B (en) | Heterocyclic compounds and uses thereof | |
| EP2637669A4 (en) | Heterocyclic compounds and their use | |
| ZA201301120B (en) | Heterocyclic compound and use thereof | |
| SG11201506093SA (en) | N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals | |
| IL250606A0 (en) | D2 antagonists, methods of synthesis and methods of use | |
| HUE054054T2 (hu) | Transz-4-{2-[4-(2,3-diklór-fenil)-piperazin-1-il]-etil}-N,N-dimetilkarbamoil-ciklohexilamin skizofrénia elsõdleges negatív tüneteinek kezelésére | |
| IL232404A0 (en) | n-(4-quinolinylmethyl)-sulfonamide derivatives and their use as anthelmintics | |
| PL2608789T5 (pl) | Terapeutyczne zastosowania 1-[2-(2,4- dimetylofenylosulfanylo)- fenylo]piperazyny | |
| AP3919A (en) | N-[4-(quinolin-4-yloxy) cyclohexyl (methyl)](hetero) arylcarboxamides as androgen receptor antagonist, production and use thereof as medicinal products | |
| EP2763980A4 (en) | BICARBOCYCLIC AND TRICARBOCYCLIC ETHYNYL DERIVATIVES AND USES THEREOF | |
| HK1183813A (en) | Ranolazine for use for the treatment of pulmonary hypertension | |
| PL392322A1 (pl) | Synton w syntezie rosuwastatyny, sposób otrzymywania syntonu w syntezie rosuwastatyny oraz zastosowanie syntonu w syntezie rosuwastatyny | |
| PL395184A1 (pl) | Nowe pochodne benzimidazolu, sposób wytwarzania i zastosowanie pochodnych benzimidazolu | |
| DE112011100444A5 (de) | Hexaorganoguanidinium-organocarbonate, ihre herstellung und ihre verwendung |